Novartis Reports Del-Desiran and Pelacarsen Phase 3 Failures

The supplied news and corroborating company releases support two material late-stage clinical outcomes: del-desiran failed its Phase III HARBOR primary endpoint on September 8, 2026, and pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes endpoint on September 4, 2026. Retaining them as a consolidated Novartis pipeline update is forward-looking because the outcomes reduce expected value from potential growth assets and affect Novartis, pelacarsen-linked economics, and explicitly identified competing programs. The development type is therefore clinical_trial_failure rather than financial_update; the sales-growth target and market-performance commentary are contextual and are not treated as separate developments. Importance is high because two late-stage failures affect a major pharmaceutical pipeline, while surprise is meaningful but below maximum because the item is a later summary of already announced results. Confidence is high because the core outcomes are directly corroborated by company releases. The occurrence timestamp uses September 8, the date of the later underlying failure rather than the September 11 publication date; the exact intraday time was not provided, so timestamp confidence is below full certainty. Approved stakeholders are limited to directly exposed companies and late-stage competitors with an explicit causal read-through; weaker early-stage or speculative links are omitted. The prior event matching is retained because the update corresponds to both existing clinical-trial-failure storylines and is not an exact duplicate of either individual development.